Symbols / NLSP
NLSP Chart
About
No company description available for this symbol.
Fundamentals
Scroll to Statements| Sector | — | Industry | — | Market Cap | — |
| Enterprise Value | — | Income | — | Sales | — |
| Book/sh | — | Cash/sh | — | Dividend Yield | — |
| Payout | — | Employees | — | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | — | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | — |
| Current Ratio | — | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | — | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | — | ROA | — |
| ROE | — | ROIC | — | Gross Margin | — |
| Oper. Margin | — | Profit Margin | — | Shs Outstand | — |
| Shs Float | — | Short Float | — | Short Ratio | — |
| Short Interest | — | 52W High | — | 52W Low | — |
| Beta | — | Avg Volume | — | Volume | — |
| Target Price | — | Recom | — | Prev Close | — |
| Price | — | Change | — |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
—
Latest analyst target
3. DCF / Fair value
—
Simplified FCF or EPS-based estimate
Ratings
No analyst ratings or price targets available.
- NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem - PR Newswire Wed, 29 Oct 2025 07
- NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares - PR Newswire Wed, 29 Oct 2025 07
- NLS Pharmaceutics stock tumbles after merger approval with Kadimastem - Investing.com Nigeria ue, 30 Sep 2025 07
- NLSP Stock Faces Highs and Lows: A Closer Look - StocksToTrade ue, 30 Sep 2025 07
- NLS Pharma (NASDAQ: NLSP) and Kadimastem secure Nasdaq listing; NewcelX to trade as NCEL - Stock Titan hu, 23 Oct 2025 07
- NLS Pharmaceutics and Kadimastem Secure Nasdaq Approval for Merger - TipRanks hu, 23 Oct 2025 07
- NLS Pharmaceutics Stock: What’s Next? - timothysykes.com ue, 30 Sep 2025 07
- 84.4% Ownership Stake: Kadimastem-NLS Pharma Merger Creates NewCelX with ALS and Diabetes Pipeline - Stock Titan ue, 30 Sep 2025 07
- Why Is NLS Pharmaceutics (NLSP) Stock Up 163% Today? - InvestorPlace ue, 18 Jun 2024 07
- NLS Pharma (NASDAQ: NLSP): BIRD support continues for ITOL‑102 at NewCelX post‑merger - Stock Titan Wed, 29 Oct 2025 07
- NLSP Stock Touches 52-Week Low at $2.98 Amid Market Challenges By Investing.com - Investing.com South Africa ue, 03 Dec 2024 08
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday - InvestorPlace ue, 18 Jun 2024 07
- Final SEC Clearance: NLS Pharma and Kadimastem to Form NewCelX, Combining CNS and Cell Therapy Platforms - Stock Titan Wed, 10 Sep 2025 07
- Tivic Health Systems (TIVC) Stock Pops Another 39% - InvestorPlace Mon, 29 Jul 2024 07
- NLS Pharmaceutics Transforms: $25M Backing Powers Merger Deal as Company Goes Debt-Free - Stock Titan Mon, 16 Jun 2025 07
Insider Transactions
No recent insider transactions.
Financials
No financial statements available. Data is sourced from Yahoo Finance and cached; historical storage may be added later.
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for NLSP
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|